Japanese Pharma Selling Obesity Drug

Japanese pharmaceutical company Eisai (TYO:4523) has developed a prescription drug that targets obesity, NorthJersey.com reported.

As quoted in the market news:

This summer, Eisai – pronounced A-zigh – began selling a prescription drug, Belviq, which has been approved as a weight-loss aid. The drug triggers serotonin receptors in the brain to create a sensation of fullness, or satiety in patients, causing them to eat less. The drug is intended only for patients who are obese – with a body mass index of 30 or greater, or overweight, with a body mass index of 27 or higher, and other health risks such as diabetes, high blood pressure or high cholesterol.

The drug went on sale June 7, and the company is averaging about 4,000 prescriptions a week.

Click here for the full article on NorthJersey.com